Acadia Pharmaceuticals (ACAD) said the FDA granted Fast Track designation to remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The designation is a positive regulatory milestone that may support faster development and review, though it does not confirm efficacy or approval. Overall, the news modestly improves the program’s outlook for investors.
Acadia Pharmaceuticals (ACAD) said the FDA granted Fast Track designation to remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The designation is a positive regulatory milestone that may support faster development and review, though it does not confirm efficacy or approval. Overall, the news modestly improves the program’s outlook for investors.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
